Safety and efficacy of oral AGN 203818 for the relief of irritable bowel syndrome pain.

Trial Profile

Safety and efficacy of oral AGN 203818 for the relief of irritable bowel syndrome pain.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Rezatomidine (Primary)
  • Indications Visceral pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2012 Planned end date changed from 1 Apr 2010 to 1 Feb 2008 as reported by ClinicalTrials.gov
    • 19 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
    • 20 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top